Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Genomics Approach Helps to Investigate Transmission of Clostridium Difficile

By LabMedica International staff writers
Posted on 02 Jan 2013
Analysis of genomes from patients treated for Clostridium difficile infections was used to investigate how the bacteria were transmitted in hospitals.

The study, which was published on December 21, 2012, in the open access journal Genome Biology, took a genomics approach to assess the incidence of patient-to-patient transmission of C. More...
difficile. The study was supported by the National Institute of Health Research Oxford Biomedical Research Center (Oxford, United Kingdom), a collaboration between Oxford University Hospitals NHS Trust and Oxford University.

A team of scientists sequenced the genomes of C. difficile isolated from 486 patients treated at four hospitals in Oxfordshire (United Kingdom) between 2006 and 2010. Scientists counted the number of genetic differences between different isolates and estimated the mutation rate of the bacteria. They were able to determine the likely time at which any two isolates became genetically separate and thus, whether the two patients in question could have plausibly caught the infection from each other in the hospital. In other words, genetic divergence implies a time-scale that can be used for judging the likelihood of direct transmission.

The results of the study indicated that, although transmission between patients could occur, it actually happens at relatively low frequency. In particular, concerns that healthcare teams were spreading infection between different hospitals seem to be misplaced. One exception to this general finding is that there were a large number of cases of infection from one particular strain that does appear to have been due to patient-to-patient transmission, emphasizing the epidemic nature of this lineage. Notably, this strain has declined in UK hospitals in the last five years.

Dr. Xavier Didelot, the study's lead author, said, "This research opens up very exciting opportunities for better understanding how bacterial infections are spread, and what we can do to stop them. The reduced cost of sequencing whole bacterial genomes means we now have the technology for identifying very recent transmissions of infection. Moreover, we can apply this technology even in cases when infection control teams have no suspicion that routes of contact between patients might exist."

Related Links:

National Institute of Health Research Oxford Biomedical Research Center





Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.